Navigation Links
QSV Biologics awarded cGMP manufacturing contract by Pfizer Inc.
Date:5/1/2008

EDMONTON, May 1 /PRNewswire/ - QSV Biologics, Ltd (QSV), a North American based biologics CMO located in Edmonton, Canada, has been awarded a cGMP manufacturing contract for a recombinant protein under development by Pfizer, Inc. The protein will be manufactured at QSV's Edmonton facility and is intended for clinical trials. Work on the project is to begin immediately, and will include technology transfer, scale-up and cGMP manufacturing.

Graeme Macaloney PhD, PEng, Founder, President & CEO of QSV said: "We are extremely pleased and honoured that Pfizer has chosen QSV Biologics from a strong field of contending CMOs as their manufacturing partner for this project. The execution of this contract is the culmination of extended evaluations by the Pfizer organization, reflecting QSV's continuing dedication to quality, speed and value. This project is an extremely good fit for our capabilities and indicative of our ability to respond to the challenging requirements of respected companies like Pfizer."

"Pfizer is pleased to engage QSV for the clinical manufacturing of a complex biotechnology product," said Rick Rutter, Ph.D., Vice President of Global Biologics in the Pharmaceutical Sciences division of Pfizer Global Research and Development. "Speed to clinic is of great importance for early development candidates and QSV has a record of delivering quality product on-time and on-budget. QSV will play a supporting role in realizing Pfizer's vision of becoming a top tier biotherapeutic company."

QSV Biologics, Ltd. (http://www.qsvbiologics.com), is an international cGMP biologics contract manufacturer (CMO) providing microbial fermentation & cell culture, and purification services. QSV's facility has a 12 yr track record including an Establishment License for manufacturing clinical trial and commercial biologics. QSV was the sole recipient of the prestigious international Frost & Sullivan "Customer Value Enhancement Award" in 2005 and the BioAlberta "Company of the Year Award" in 2007. QSV's global clientele spans 3 continents and develops protein therapeutics, vaccines & diagnostics. As a dedicated CMO with no competing products of its own, QSV builds value for its clients by producing quality products in a timely manner. Hence its acronym: QSV: Quality & Speed build Value.


'/>"/>
SOURCE QSV Biologics, Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Specialists Are Turning to Biologics Earlier in the Treatment of Psoriasis and Psoriatic Arthritis
2. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
3. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
4. Biotest Pharmaceuticals Corporation Completes Acquisition of Nabi Biologics Business Unit
5. Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant
6. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
7. MedImmune Submits Biologics License Application to FDA for Motavizumab
8. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
9. Study by Leading Economist Identifies Potential for $378 Billion of Savings From Follow On Biologics
10. Biologics, Derma Fillers are Key to Dermatological Drug Market Growth
11. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... May 23, 2017 , ... Genedata, a leading provider of ... occasion with a strong presence at Bio-IT World Conference & Expo 2017 in ... invitation to all attendees to view posters on the entire range of ...
(Date:5/23/2017)... PARK, CA (PRWEB) , ... May 23, 2017 , ... ... the publication of “Label-free isolation of prostate circulating tumor cells using Vortex microfluidic ... is the result of a collaboration with Dr. Dino Di Carlo and Dr. Matthew ...
(Date:5/23/2017)... CA (PRWEB) , ... May 23, 2017 , ... Bacterial ... of polymeric molecules, can cause diverse pathologies ranging from food poisoning and catheter infections ... of biofilms is in the tens of billions of dollars per year, there is ...
(Date:5/22/2017)... MA (PRWEB) , ... May 22, 2017 , ... Stratevi, ... has expanded to the East Coast. It has opened an office in downtown Boston ... therapies are finding it increasingly more important to generate evidence on the value they ...
Breaking Biology Technology:
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" or ... independent Directors Mr. Robin D. Richards and Mr. ... the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer said," ... and benefiting from their considerable expertise as we move forward ...
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
(Date:3/30/2017)... KONG , March 30, 2017 The ... a system for three-dimensional (3D) fingerprint identification by adopting ground breaking ... into a new realm of speed and accuracy for use in ... at an affordable cost. ... ...
Breaking Biology News(10 mins):